When was Unity Biotechnology founded?

Unity Biotechnology was founded in 2009 and raised its 1st funding round 7 years after it was founded.

Where is Unity Biotechnology located?

Unity Biotechnology is headquartered in San Francisco, United States.

How many employees does Unity Biotechnology have?

As of Mar 31, 2026, the latest employee count at Unity Biotechnology is 19.

Is Unity Biotechnology a funded company?

Unity Biotechnology is a funded company, having raised a total of $206M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 03, 2016.

When was the latest funding round of Unity Biotechnology?

Unity Biotechnology's latest funding was a $***** Conventional Debt round on Aug 04, 2020, with participation from 1 investor.

What is the annual revenue of Unity Biotechnology?

Annual revenue of Unity Biotechnology is $236K as on Dec 31, 2022.

Where does Unity Biotechnology rank among its competitors?

Unity Biotechnology ranks 5th amongst 19 active competitors, of which 10 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Seabelife, which secured $2.35M in Oct, 2025.

Who are the top competitors of Unity Biotechnology?

Unity Biotechnology's top competitors include Eyestem, Character Biosciences and PulseSight. Among them, Seabelife secured the most recent funding round in October, 2025.

Unity Biotechnology - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics solutions for numerous diseases of aging. It offer therapeutics that prevent, halt, and reverse various diseases of aging. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. It has shown that removing senescent cells from animals reverses or prevents many conditions in which senescent cells are implicated, including osteoarthritis, atherosclerosis, eye diseases, and kidney diseases. The company has used a biomarker for senescence, p16(Ink4a), to design a novel transgene, INK-ATTAC, for inducible elimination of p16(Ink4a)-positive senescent cells upon administration of a drug.

Website: unitybiotechnology.com
Social

Key Metrics

Founded Year

2009

Location

San Francisco, United States

Stage

Deadpooled

Total Funding

$206M in 5 rounds

Latest Funding Round

Conventional Debt, Aug 04, 2020, $*****

Investors

Arch Venture Partners & 22 more

Ranked

5^th among 19 active competitors

Annual Revenue

$236K as on Dec 31, 2022

Employee Count

19 as on Mar 31, 2026

Similar Companies

Eyestem & 18 more

View Unity Biotechnology's full profile

Unity Biotechnology is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
UNITY Biotechnology, Inc. Belgium, Active	Mar 29, 2009	-	-	-
Unity Biotechnology, Inc. CIN: 1463361 , United States, Active	Mar 29, 2009	$236K (As on Dec 31, 2022)	-	-

Unity Biotechnology has raised a total funding of $206M over 5 rounds. Its first funding round was on Feb 03, 2016. Its latest funding round was a Conventional Debt round on Aug 04, 2020 for $*****. 1 investor participated in its latest round. Unity Biotechnology has 23 institutional investors.

Here is the list of recent funding rounds of Unity Biotechnology:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 04, 2020	3022030	Conventional Debt	7934150	3896529	8810518	9937763
Mar 19, 2018	3355272	Series C	1784113	3147211	7539021	6 Dimensions Capital & 10 more
Aug 17, 2017	8012189	Series B	7426136	1214332	Arch Venture Partners	Cycad Group & 10 more

Access funding benchmarks and valuations. Sign up today!

View details of Unity Biotechnology's funding rounds and investors

The founders of Unity Biotechnology are Nathaniel David, Daohong Zhou, Judith Campisi and Jan van Deursen.

Here are the details of Unity Biotechnology's key team members:

Nathaniel David: Former Co-Founder of Unity Biotechnology and founder of 1 other company.
Contact Info: 1 email address
Daohong Zhou: Former Co-Founder of Unity Biotechnology.
Judith Campisi: Former Co-Founder of Unity Biotechnology.
Jan van Deursen: Former Co-Founder of Unity Biotechnology.

View details of Unity Biotechnology's Founder profiles and Board Members

Unity Biotechnology's employee count trend

Unity Biotechnology has 19 employees as of Mar 26. Here is Unity Biotechnology's employee count trend over the years:

Employee count trend for Unity Biotechnology

Uncover Unity Biotechnology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Unity Biotechnology include Eyestem, Character Biosciences and PulseSight. Here is the list of Top 10 competitors of Unity Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Eyestem 2015, Bengaluru (India), Series B	Developer of cell replacement therapies to treat ophthamological conditions	$19.9M	Kotak Investment Advisors, Endiya Partners ... & 24 others	61/100
2nd	Character Biosciences 2019, San Carlos (United States), Series B	Developer of therapeutics for the treatment of age-related eye diseases	$120M	Innovation Endeavors, aMoon & 11 others	56/100
3rd	PulseSight 2008, Paris (France), Series B	Developer of non-viral minimally invasive gene therapies for retinal diseases	$54.2M	ND Capital, Pureos Bioventures & 9 others	55/100
4th	Seabelife 2019, Roscoff (France), Seed	Developer of drugs to prevent necrosis and treat diseases affecting major organs	$8.32M	iXLife Capital, Bpifrance & 9 others	52/100
5th	Unity Biotechnology 2009, San Francisco (United States), Deadpooled	Developer of therapeutics solutions for numerous diseases of aging	$206M	Fidelity Investments, EcoR1 & 21 others	52/100
6th	RevOpsis 2018, Dover (United States), Seed	Developer of therapeutics to treat ophthalmic diseases	$17.2M	Exsight Ventures, HHS	51/100
7th	Luxa 2019, Fort Lee (United States), Funding Raised	Developer of stem cell therapies for Age-related macular degeneration	-	State of California	37/100
8th	Ruichu Pharmaceutical 2021, Nanjing (China), Seed	Developer of therapeutics for aging-related diseases	-	Delian Capital, Dingxin Capital & 1 others	36/100
9th	Ruiming New Drug 2018, Suzhou (China), Series B	Developer of small molecule therapeutics for ophthalmic diseases	$15.7M	crlifesciences.com, Beijing Fangyuan Jinding Investment Management ... Read more	35/100
10th	PlantForm 2008, Ontario (United States), Series A	Cultivation of genetically modified tobacco plants and processing to supply medicinal products	$2M	Lynx Financial, MaRS Discovery District & 3 others	34/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Unity Biotechnology's competitors? Click here to see the top ones

Unity Biotechnology has made no investments or acquisitions yet.

Here is the latest report on Unity Biotechnology's sector:

Free

Neurology - Sector Report

Edition: May, 2025 (86 Pages)

View all reports related to Unity Biotechnology

Media has covered Unity Biotechnology for a total of 8 events in the last 1 year, 4 of them have been about company updates and 1 about people movement.